Angiotensin receptor blocker attacks armored and cold tumors and boosts immune checkpoint blockade

• DOI: 10.1136/jitc-2024-009327
• Publication Date: 2024-09-07T07:48:36Z
• Authors: Jie Mei; Jiahui Chu; Kai Yang; Zhiwen Luo; Jiayue Yang; Junying Xu; Qing Li; Yan Zhang; Qinglin Zhang; Mengyun Wan; Ningyi Xue; Junli Ding; Yichao Zhu; Yun Cai; Yongmei Yin
• Keywords: Immune checkpoint

Immune checkpoint blockade (ICB) has made remarkable achievements, but newly identified armored and cold tumors cannot respond to ICB therapy. The high prevalence of concomitant medications huge impact on immunotherapeutic responses, the clinical effects therapeutic outcome are still unclear.